clinical trial · NCT06791525
Tirbanibulin for Pediatric Warts
The Skin Center Dermatology Group·phase4·recruiting·n = 10
Warts HandTirbanibulin ointment 1%
brief summary
Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.
started
May 1, 2025
primary completion
Nov 1, 2026
completion
Dec 30, 2026
last updated
Apr 23, 2026
official title
Single-arm, Open-label Study of Tirbanibulin 1% Ointment to Treat Warts on the Hands in Pediatric Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol